Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine

Dementia and Geriatric Cognitive Disorders

Volumn 23, Issue 5, 2007, Pages 301-306

  Riepe, Matthias W ^a   Adler, Georg ^b   Ibach, Bernd ^c   Weinkauf, Birgit ^d   Tracik, Ferenc ^d   Gunay, Ibrahim ^e  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^c UNIVERSITY OF REGENSBURG   (Germany)

^d Clinical Research Novartis Pharma GmbH   (Germany)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Alzheimer's disease; Memantine; Neuropsychological tests; Rivastigmine

Indexed keywords

ACETYLCARNITINE; ALPHA TOCOPHEROL; DIHYDROERGOTOXINE MESILATE; ESTROGEN; MEMANTINE; NOOTROPIC AGENT; PIRACETAM; PSYCHOTROPIC AGENT; RIVASTIGMINE;

ADD ON THERAPY; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; DRUG DOSE INCREASE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ATTENTION; CHOLINESTERASE INHIBITORS; COGNITION; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; HUMANS; MALE; MEMANTINE; MEMORY; PHENYLCARBAMATES; PILOT PROJECTS; RECEPTORS, N-METHYL-D-ASPARTATE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 34247391488     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000100875     Document Type: Article

References (47)

1. Cummings JL: Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry 2003;11:131-145.
2. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M: Rivastigmine for Alzheimer's disease. Cochrane Database Syst Rev 2000:CD001191.
3. Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, Loulou MM, Einarson TR: Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. CMAJ 2003;169:557-564.
4. Lamb HM, Goa KL: Rivastigmine: a pharmacoeconomic review of its use in Alzheimer's disease. Pharmacoeconomics 2001;19:303-318.
5. Neumann PJ, Hermann RC, Kuntz KM, Araki SS, Duff SB, Leon J, Berenbaum PA, Goldman PA, Williams LW, Weinstein MC: Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology 1999;52:1138-1145.
6. Rosler M: The efficacy of cholinesterase inhibitors in treating the behavioural symptoms of dementia. Int J Clin Pract Suppl 2002:20-36.
7. Giacobini E, Spiegel R, Enz A, Veroff AE, Cutler NR: Inhibition of acetyl- and butyrylcholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. J Neural Transm 2002;109:1053-1065.
8. Darreh-Shori T, Almkvist O, Guan ZZ, Garlind A, Strandberg B, Svensson AL, Soreq H, Hellstrom-Lindahl E, Nordberg A: Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months. Neurology 2002;59:563-572.
9. Areosa SA, Sherriff F: Memantine for dementia. Cochrane Database Syst Rev 2003:CD003154.
10. Parsons CG, Danysz W, Quack G: Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - a review of preclinical data. Neuropharmacology 1999;38:735-767.
11. 1-40 . Brain Res 2002;958:210-221.
12. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341.
13. Ruther E, Glaser A, Bleich S, Degner D, Wiltfang J: A prospective PMS study to validate the sensitivity for change of the D-scale in advanced stages of dementia using the NMDA-antagonist memantine. Pharmacopsychiatry 2000;33:103-108.
14. Winblad B, Poritis N: Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-146.
15. Wimo A, Winblad B, Stoffler A, Wirth Y, Mobius HJ: Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics 2003;21:327-340.
16. Ambrozi L, Danielczyk W: Treatment of impaired cerebral function in psychogeriatric patients with memantine - results of a phase II double-blind study. Pharmacopsychiatry 1988;21:144-146.
17. Doody R, Wirth Y, Schmitt F, Mobius HJ: Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord 2004;18:227-232.
18. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-324.
19. Riepe MW, Adler G, Ibach B, Weinkauf B, Gunay I, Tracik F: Adding memantine to therapy with rivastigmine in patients with mild to moderate Alzheimer's disease: results of a 12-week pilot study. Prim Care Companion J Clin Psychiatry 2006;8:258-263.
20. Shanks MF, Venneri A: Conventional trial designs offer limited clinical understanding of cholinesterase-inhibitor treatment effects in Alzheimer disease. Am J Geriatr Psychiatry 2005;13:170.
21. Venneri A, Shanks MF, Staff RT, Pestell SJ, Forbes KE, Gemmell HG, Murray AD: Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport 2002;13:83-87.
22. Folstein MF, Folstein SE, McHugh PR: 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
23. Lezak M: Neuropsychological Assessment. New York, Oxford University Press, 1995.
24. Bentue-Ferrer D, Tribut O, Polard E, Allain H: Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists. CNS Drugs 2003;17:947-963.
25. Enz A, Gentsch C: Co-administration of memantine has no effect on the in vitro or ex vivo determined acetylcholinesterase inhibition of rivastigmine in the rat brain. Neuropharmacology 2004;47:408-413.
26. Weyer G, Erzigkeit H, Kanowski S, Ihl R, Hadler D: Alzheimer's Disease Assessment Scale: reliability and validity in a multicenter clinical trial. Int Psychogeriatr 1997;9:123-138.
27. Nordberg A, Svensson AL: Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf 1998;19:465-480.
28. Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Scherer J, Gulanski B: The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology 1997;48:1511-1517.
29. Doraiswamy PM, Kaiser L, Bieber F, Garman RL: The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Alzheimer Dis Assoc Disord 2001;15:174-183.
30. Burns A, Spiegel R, Quarg P: Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Int J Geriatr Psychiatry 2004;19:243-249.
31. Braak H, Braak E: Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991;82:239-259.
32. Hyman BT, Van Horsen GW, Damasio AR, Barnes CL: Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science 1984;225:1168-1170.
33. Hodges JR: Memory in the dementias; in Tulving E, Craik FIM (eds): The Oxford Handbook of Memory. New York, Oxford University Press, 2000, pp 441-459.
34. Gron G, Bittner D, Schmitz B, Wunderlich AP, Riepe MW: Subjective memory complaints: objective neural markers in patients with Alzheimer's disease and major depressive disorder. Ann Neurol 2002;51:491-498.
35. Gron G, Riepe MW: Neural basis for the cognitive continuum in episodic memory from health to Alzheimer disease. Am J Geriatr Psychiatry 2004;12:648-652.
36. 18F]FDG-PET in patients with Alzheimer's disease: marker of disease spread. Dement Geriatr Cogn Disord 2004;19:24-30.
37. Marshall JC, Fink GR: Spatial cognition: where we were and where we are. Neuroimage 2001;14:S2-S7.
38. Save E, Poucet B: Hippocampal-parietal cortical interactions in spatial cognition. Hippocampus 2000;10:491-499.
39. Godefroy O, Cabaret M, Petit-Chenal V, Pruvo JP, Rousseaux M: Control functions of the frontal lobes: modularity of the central-supervisory system? Cortex 1999;35:1-20.
40. Nagahama Y, Okada T, Katsumi Y, Hayashi T, Yamauchi H, Oyanagi C, Konishi J, Fukuyama H, Shibasaki H: Dissociable mechanisms of attentional control within the human prefrontal cortex. Cereb Cortex 2001;11:85-92.
41. Rowe JB, Toni I, Josephs O, Frackowiak RS, Passingham RE: The prefrontal cortex: response selection or maintenance within working memory? Science 2000;288:1656-1660.
42. Vanderploeg RD, Schinka JA, Retzlaff P: Relationships between measures of auditory verbal learning and executive functioning. J Clin Exp Neuropsychol 1994;16:243-252.
43. Waters GS, Caplan D: The reliability and stability of verbal working memory measures. Behav Res Methods Instrum Comput 2003;35:550-564.
44. Carlesimo GA, Fadda L, Lorusso S, Caltagirone C: Verbal and spatial memory spans in Alzheimer's and multi-infarct dementia. Acta Neurol Scand 1994;89:132-138.
45. Collette F, Salmon E, Van der Linden M, Degueldre C, Franck G: Functional anatomy of verbal and visuospatial span tasks in Alzheimer's disease. Hum Brain Mapp 1997;5:110-118.
46. Kitabayashi Y, Ueda H, Tsuchida H, Iizumi H, Narumoto J, Nakamura K, Kita H, Fukui K: Relationship between regional cerebral blood flow and verbal fluency in Alzheimer's disease. Psychiatry Clin Neurosci 2001;55:459-463.
47. Pihlajamaki M, Tanila H, Hanninen T, Kononen M, Laakso M, Partanen K, Soininen H, Aronen HJ: Verbal fluency activates the left medial temporal lobe: a functional magnetic resonance imaging study. Ann Neurol 2000;47:470-476.